Últimas noticias sobre Biohaven (NYSE:BHVN) Bolsa

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Biohaven Ltd

Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) disclosed that Sony Pictures Entertainment&#8217;s (SPE) Chairman and <a target="_blank" href="https://www.sonypictures.com/corp/press_releases/2024/0930#:~:text=TOKYO%20(October%201%2C%202024),assume%20leadership%20of%20SPE%20as" rel="noreferrer noopener">CEO </a>Tony Vinciquerra will step down from his post.
Sony Pictures Entertainment appointed Ravi Ahuja, current Chairman of Global Television Studios and President and COO, as the new President and CEO, effective January 2, 2025.
Vinciquerra will serve as non-executive Chairman for SPE in an advisory role until December 2025.
Ravi Ahuja joined SPE in 2021 as Chairman of Global Television Studios, overseeing Sony Pictures Television&#8217;s (SPT) production businesses and operations in India.
Under his leadership, SPT has produced acclaimed series like The Crown, The Boys, Cobra Kai, and American Idol.
Yoshida commented, &#8220;Under Tony&#8217;s watch, SPE became a critically important part of our efforts to maximize the value of our IP and find synergies across all our entertainment and technology businesses, and it remains a key driver in Sony Group&#8217;s ongoing corporate strategies to lean further into the creative and entertainment spaces.&#8221;
&#8220;Since joining SPE in 2021, Ravi has been at the center of Tony&#8217;s leadership team, navigating the unprecedented challenges of today&#8217;s media and entertainment environment and positioning SPE for further growth. Ravi brings with him years of experience from his time at some of the world&#8217;s most successful entertainment companies, and we look forward to working more closely with him in his new role as President and CEO of SPE.&#8221;
Last month, Sony announced the PlayStation Plus lineup for October 2024, featuring WWE 2K24,<a target="_blank" href="https://www.benzinga.com/general/gaming/24/09/41030256/playstation-plus-october-lineup-revealed-wwe-2k24-dead-space-more" rel="noreferrer noopener"> Dead Space Remake, and more</a>.
Investors can gain access to the stock via&nbsp;BlackRock Large Cap Core ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLCR#NASDAQ">BLCR</a>) and&nbsp;American Century ETF Trust Avantis Responsible International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVSD#NYSE">AVSD</a>).
Price Action: SONY shares are up 0.62% at $97.17 at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/41100852/ps5-users-blast-new-ads-on-dashboard-cant-be-disabled-without-internet-disconnect" target="_blank" rel="noreferrer noopener">PS5 Users Blast New Ads On Dashboard: Can&#8217;t Be Disabled Without Internet Disconnect</a></li>
</ul>

Entertainment

Equities

Large Cap

News

Management

General

American Century ETF Trust Avantis Responsible International Equity ETF

AVSD

BLCR

Sony Group Corporation American Depositary Shares

SONY

Sony's Power Play: Ravi Ahuja To Lead Sony Pictures Entertainment After CEO Shake-Up

WIIM

Dine Brands Global shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $34 to $47.

Trading Ideas

New Fortress Energy Shares Resume Trade Following Circuit Breaker Halt

CTLP

Cantaloupe shares are trading higher after the company announced its chairman and CEO have recently increased their positions in the stock.

UBS analyst Kevin Mcveigh initiates coverage on Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy rating and announces Price Target of $360.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Equifax with Buy Rating, Announces Price Target of $360

<a href="https://x.com/BarakRavid/status/1841109007441735757" title="https://x.com/BarakRavid/status/1841109007441735757">https://x.com/BarakRavid/status/1841109007441735757</a>

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Axios Reporter, Barak Ravid, Post On X, 'Senior White House Official tells me: "The United States has indications that Iran is preparing to imminently launch a ballistic missile attack against Israel"'

Citigroup analyst Ryan Levine downgrades Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Buy to Neutral and lowers the price target from $32 to $24.

Downgrades

FLNC

Citigroup Downgrades Fluence Energy to Neutral, Lowers Price Target to $24

Pharmaceutical giant Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is reportedly exploring broader applications for its popular weight-loss drugs, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38055169/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-le" rel="noreferrer noopener">Mounjaro and Zepbound</a>.
The company is considering clinical trials targeting individuals with a lower body mass index (BMI), expanding beyond the obese patient population to include those not classified as overweight but at risk of gaining weight.
In a Financial Times <a target="_blank" href="https://www.ft.com/content/b2da2ca6-822e-4d42-bee4-e500522531e7" rel="noreferrer noopener">report</a>, CEO Dave Ricks highlighted the company&#8217;s plans to study the effects of these medications on people with a BMI of 25, compared to the standard BMI threshold of 27 in Europe and the U.S. for clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation" rel="noreferrer noopener">Battle Over Compounded Weight-Loss Medications &#8211; Sustainability and Regulation</a>.
Ricks hinted that the company&#8217;s long-term goal may involve using GLP-1 class drugs for overall health maintenance.
He told FT that these drugs might benefit people who are not yet overweight but are seeking to prevent conditions such as diabetes, vascular dementia, or strokes.
Eli Lilly has already been studying Zepbound in patients with a BMI of 27 or above, especially those facing weight-related health issues, but is now considering lowering that threshold to include more individuals, particularly for its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener">experimental weight-loss pill</a>, orforglipron.
Eli Lilly has also been vocal in discouraging the use of Zepbound for cosmetic purposes, particularly among wealthy individuals and celebrities using the drug off-label.
The company has argued that the limited supply of these medications should be reserved for diabetic and obese patients who need them most.
Ricks reiterated the company&#8217;s stance, saying they are &#8220;not comfortable&#8221; with the drug&#8217;s off-label use for vanity.
In a bold move, Eli Lilly aired a commercial during the Academy Awards to emphasize that Zepbound should not be used simply to fit into a smaller dress or tuxedo for a special event.
Price Action: LLY stock is up 0.32% at $888.73 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41116026/mccormick-stock-gains-after-q3-earnings-beat-raised-eps-outlook" target="_blank" rel="noreferrer noopener">McCormick Stock Gains After Q3 Earnings Beat, Raised EPS Outlook</a>.</li>
</ul>
Image by Mohammed_Al_Ali via Shutterstock

Biotech

Health Care

Media

Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients

From lagging on perception regarding prowess to handle the economy, <a href="https://benzinga.grsm.io/register174">Vice President Kamala Harris </a>has come a long way so much so that her policy proposals now strike a chord with the public. The results of a recent survey confirmed this.
Trump Vs. Harris: In a blind test of the policy proposals of Harris and her Republican rival Donald Trump, the former&#8217;s was favored by voters, a new Harris Poll commissioned by Guardian <a href="https://www.theguardian.com/us-news/2024/sep/30/harris-trump-economic-proposals-poll">showed.</a> Four of the most popular policy proposals picked by the public belonged to the Democratic campaign, the poll found. 
The survey was conducted online nationally from Sept. 12-14 among 2,122 respondents, with the margin of error at +/- percentage points.
The respondents were given a list of 12 policy proposals &#8211; six belonging to Trump&#8217;s campaign and the remaining six to Harris&#8217;, without revealing which campaign these proposals came from. The most popular proposal was the federal ban on price-gouging of food and groceries that was put forward by the vice president. Forty-five percent of the respondents said this measure would strengthen the economy.
The Democratic campaign has pitched the clampdown on price gouging as a means to bring down inflation, which is the top election issue. Sixty-six percent of the respondents surveyed in the Harris poll mentioned the cost of living as their biggest economic concern.
The second most preferred proposal was from the Trump campaign, with 42% backing the former president&#8217;s plan to eliminate taxes on Social Security benefits. 
The third, fourth and fifth preferred proposals were expanding the child tax credit for middle- and low-income families (33%), tax breaks for new small businesses (33%) and increasing the tax rate on long-term capital gains for those earning over a million dollars (29%), all of which were suggested by the Harris camp. 
Trump&#8217;s proposal to deport millions of migrants was approved by 43% of the Republicans but only 24% of the independents and 15% of the Democrats favored it. 
More independents favored the vice president&#8217;s policies than Trump&#8217;s, the poll found.
See Also: <a href="https://www.benzinga.com/news/24/10/41110135/trumps-niece-says-vance-handed-down-huge-advantage-in-debate-with-walz-labels-him-inveterate-liar">Trump&#8217;s Niece Says Vance Handed Down Huge &#8216;Advantage&#8217; In Debate With Walz, Labels Him &#8216;Inveterate Liar&#8217;</a>
Harris&#8217; Shift Helping? In a shift away from Bidenomics &#8211; a name used to refer to President Joe Biden&#8217;s economic policies, Harris has been focusing on rising costs, the report said. This has been welcomed by younger Americans, which now account for a big chunk of voters. The poll found that 87% of millennials and Gen Z voters said at least one of Harris&#8217; policies was good compared to 79% of these demographics who said the same about Trump&#8217;s policies. The majority of millennials (59%) said that Harris' policies are better than Biden's, compared to just 36% of Boomers.
&#8220;Despite some skepticism that VP Harris has yet to define where she stands, our data shows she's energized her base – particularly millennials, who will be the largest voting bloc this election – by effectively messaging and connecting with them on the issues they are facing as they move more into adulthood: childcare, housing and jobs," said John Gerzema, CEO of Harris Poll.
Most Americans are still feeling sore about the economy. Even after several economic measures improved, 35% of respondents said they were more pessimistic, while 29% felt more optimistic. Nearly three-quarters (73%) of all polled said they did not feel any positive effects of good economic news today.
A majority of Americans (61%) believe inflation is increasing when it has actually fallen significantly from its peak in 2022. And nearly half of those polled, 49%, said they believed the US economy was experiencing a recession.
Despite inflationary pressure subsiding, a majority (61%) said pricing pressure was on the rise, while 49% said the economy was in a recession.
On a positive note, 61% felt better about their personal finances and 72% were happy with their ability to afford necessities.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Shutterstock

Politics

Economics

Trump Vs. Harris: Poll Finds Vice President Has Energized This Largest Voting Bloc As Her Economic Proposals Strike A Chord

Nano Labs shares are trading higher after the company announced its CEO purchased 1,107,935 Class A shares with his personal funds.

<a href="https://news.bloomberglaw.com/environment-and-energy/meta-zuckerberg-must-face-investor-suit-over-young-user-harm">https://news.bloomberglaw.com/environment-and-energy/meta-zuckerberg-must-face-investor-suit-over-young-user-harm</a>
Meta Platforms Inc., Mark Zuckerberg, and others must face an investor lawsuit that says they made misstatements about its content management, a federal district court said.
The plaintiffs, for example, have shown that some statements about Instagram's affect on young users were false, Judge Araceli Martinez-Olguin of the US District Court for the Northern District of California said in a Monday order partially denying the defendants' motion to dismiss.
Plaintiffs Ohio Public Employees Retirement System and PFA Pension Forsikringsaktieselskab sued in 2021, alleging violations of the Securities and Exchange Act.
Bernstein Litowitz Berger &amp; Grossmann LLP represents the plaintiff. ...
 &nbsp;

Legal

'Meta, Zuckerberg Must Face Investor Suit Over Young User Harm' - Bloomberg Law

JMP Securities analyst Trevor Walsh reiterates Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Market Outperform and maintains $27 price target.

Reiteration

KTOS

JMP Securities Reiterates Market Outperform on Kratos Defense & Security, Maintains $27 Price Target

Citigroup analyst Joanna Wiensch upgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Neutral to Buy and raises the price target from $255 to $275.

Upgrades

Citigroup Upgrades Becton Dickinson to Buy, Raises Price Target to $275

JMP Securities analyst Joey Marincek reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Market Outperform and maintains $30 price target.

JAMF

JMP Securities Reiterates Market Outperform on Jamf Holding, Maintains $30 Price Target

Capability upgrade will counter new adversary threats

Contracts

RTX's Raytheon Awarded $192M U.S. Navy Contract For Next Generation Jammer Mid-Band Expansion

Citigroup analyst Patrick Donnelly downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Buy to Neutral and lowers the price target from $95 to $85.

HOLX

Citigroup Downgrades Hologic to Neutral, Lowers Price Target to $85

Energy Ministry Says Guyana Expects To Receive Bids On Tuesday For Crude Marketing Contract

ARCO

Arcos Dorados shares are trading higher after the company announced plans to exercise its option to new its master franchise agreement with McDonald's.

CoStar Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NYSE">CSGP</a>) short percent of float has risen 8.72% since its last report. The company recently reported that it has 8.09 million shares sold short, which is 2.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CoStar Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789427_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CoStar Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CoStar Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CoStar Gr's peer group average for short interest as a percentage of float is 6.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CSGP

How Is The Market Feeling About CoStar Gr?

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 6.09% since its last report. The company recently reported that it has 33.53 million shares sold short, which is 26.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 13.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NVAX

Looking Into Novavax's Recent Short Interest

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $68.00. T...

RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $58.00....

Buy Rating Affirmed for Biohaven Ltd. on Strong Potential of Troriluzole for Spinocerebellar Ataxia

Analyst Thomas Shrader from BTIG maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $59.00. Thomas S...

Buy Rating for Biohaven's Troriluzole Backed by Long-Term Efficacy Data and Positive Regulatory Outlook

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price targe...

Buy Rating Affirmed for Biohaven Ltd. on Promising Troriluzole SCA Program Data and Potential Market Dominance

In a report released yesterday, William Pickering from Bernstein maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price ta...

Bernstein Remains a Buy on Biohaven Ltd. (BHVN)

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on BHVN stock, giving a Buy rating today. Tessa Romero has given his Buy ratin...

Buy Rating Affirmed for Biohaven on Promising Troriluzole SCA Study Results and FDA Approval Potential

Biohaven Ltd. (BHVN) has received a new Buy rating, initiated by Jefferies analyst, Amy Li. Amy Li's rating is based on the promising outcomes of B...

Biohaven Ltd.: Strong Buy Rating on Troriluzole's Promising SCA Study and FDA Alignment

Biohaven proposed public offering of common shares

Biohaven prices $250M share offering

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of...

TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)

BHVN

Earnings

Press Releases

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Offerings

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

BNTC

REGN

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Denali Therapeutics

Dyne Therapeutics

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Biohaven

Noticias

Últimas noticias sobre Biohaven (NYSE:BHVN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL